R. Marcus, A. Davies, and K. Ando, Obinutuzumab for the first-line treatment of follicular lymphoma, N Engl J Med, vol.377, pp.1331-1375, 2017.

G. Salles, J. F. Seymour, and F. Offner, Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial, Lancet, vol.377, pp.42-51, 2011.
DOI : 10.1016/s0140-6736(10)62175-7

G. A. Salles, J. F. Seymour, and P. Feugier, Long term follow-up of the PRIMA study: half of patients receiving rituximab maintenance remain progression free at 10 years, Blood, vol.130, 2017.

I. W. Flinn, R. Van-der-jagt, and B. S. Kahl, Randomized trial of bendamustinerituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study, Blood, vol.123, pp.2944-52, 2014.

M. J. Rummel, N. Niederle, and G. Maschmeyer, Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 noninferiority trial, Lancet, vol.381, pp.1203-1213, 2013.
DOI : 10.1016/s0140-6736(12)61763-2

R. Kridel, L. H. Sehn, and R. D. Gascoyne, Pathogenesis of follicular lymphoma, J Clin Invest, vol.122, pp.3424-3455, 2012.

G. A. Salles, Clinical features, prognosis and treatment of follicular lymphoma, Hematology Am Soc Hematol Educ Program, pp.216-241, 2007.
DOI : 10.1182/asheducation-2007.1.216

URL : http://asheducationbook.hematologylibrary.org/content/2007/1/216.full.pdf

S. M. Hubbard, B. A. Chabner, . Devita, and . Vt, Histologic progression in nonHodgkin's lymphoma, Blood, vol.59, pp.258-64, 1982.

A. K. Gandhi, J. Kang, and C. G. Havens, Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3

, Br J Haematol, vol.164, pp.811-832, 2014.

A. Lopez-girona, D. Mendy, and T. Ito, Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide, Leukemia, vol.26, pp.2326-2361, 2012.

C. C. Bjorklund, L. Lu, and J. Kang, Rate of CRL4(CRBN) substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4, Blood Cancer J, vol.5, p.354, 2015.

H. Chiu, P. R. Hagner, P. Trisal, M. Waldman, C. Cavanaugh et al., Combination of lenalidomide and rituximab (R 2 ) targets immune dysfunction in FL by activating T and NK cells ex vivo and is differentiated from chemotherapy, Clin Cancer Res, vol.130, pp.5984-92, 2005.

K. Lagrue, A. Carisey, D. J. Morgan, R. Chopra, and D. M. Davis, Lenalidomide augments actin remodeling and lowers NK-cell activation thresholds, Blood, vol.126, pp.50-60, 2015.

N. Reddy, F. J. Hernandez-ilizaliturri, and G. Deeb, Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo

, Br J Haematol, vol.140, pp.36-45, 2008.

L. Zhang, Z. Qian, and Z. Cai, Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo, Am J Hematol, vol.84, pp.553-562, 2009.

A. G. Ramsay, A. J. Clear, and G. Kelly, Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment, INSERM DISC DOC on November, vol.22, p.379, 2018.
DOI : 10.1182/blood-2009-04-217687

URL : http://www.bloodjournal.org/content/bloodjournal/114/21/4713.full.pdf

, Rituximab plus Lenalidomide in Follicular Lymphoma and immunotherapy, Blood, vol.114, pp.4713-4733, 2009.

N. Fowler, Extended dosing lenalidomide with intensified rituximab in untreated indolent NHL, Hematol Oncol, vol.33, pp.200-201, 2015.

N. H. Fowler, R. E. Davis, and S. Rawal, Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial, Lancet Oncol, vol.15, pp.1311-1319, 2014.

E. Kimby, S. Rondeau, and A. Vanazzi, Rituximab plus lenalidomide versus rituximab monotherapy in untreated follicular lymphoma patients in need of therapy: first analysis of survival endpoints of the randomized phase-2 trial SAKK 35/10, Blood, vol.128, p.1099, 2016.

P. Martin, S. H. Jung, and B. Pitcher, A phase II trial of lenalidomide plus rituximab in previously untreated follicular non-Hodgkin's lymphoma (NHL): CALGB 50803 (Alliance), Ann Oncol, vol.28, pp.2806-2818, 2017.

P. Brice, Y. Bastion, and E. Lepage, Comparison in low-tumor-burden follicular lymphomas between an initial notreatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires, J Clin Oncol, vol.15, pp.1110-1117, 1997.

J. Crawford, C. Caserta, and F. Roila, Hematopoietic growth factors: ESMO Clinical Practice Guidelines for the applications

T. J. Smith, K. Bohlke, and G. H. Lyman, Recommendations for the use of WBC growth factors: American Society of Clinical Oncology clinical practice guideline update, J Clin Oncol, vol.21, pp.3199-212, 2010.

B. D. Cheson, S. J. Horning, and B. Coiffier, Report of an international workshop to standardize response criteria for nonHodgkin's lymphomas, J Clin Oncol, vol.17, p.1244, 1999.

Q. Shi, C. R. Flowers, and W. Hiddemann, Thirty-month complete response as a surrogate end point in first-line follicular lymphoma therapy: an individual patientlevel analysis of multiple randomized trials, J Clin Oncol, vol.35, pp.552-60, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01800000

M. Gail and R. Simon, Testing for qualitative interactions between treatment effects and patient subsets, Biometrics, vol.41, pp.361-72, 1985.

H. Schulz, J. F. Bohlius, and S. Trelle, Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis, J Natl Cancer Inst, vol.99, pp.706-720, 2007.

C. Casulo, W. R. Burack, and J. W. Friedberg, Transformed follicular non-Hodgkin lymphoma, Blood, vol.125, pp.40-47, 2015.

B. K. Link, M. J. Maurer, and G. S. Nowakowski, Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the University of Iowa/MayoClinic Specialized Program of Research Excellence Molecular Epidemiology Resource, J Clin Oncol, vol.31, pp.3272-3280, 2013.

A. Dumortier, P. Kirstetter, P. Kastner, and S. Chan, Ikaros regulates neutrophil differentiation, Blood, vol.101, pp.2219-2245, 2003.